Will you use ovarian function suppression in lieu of chemotherapy in premenopausal patients with pN1 ER+ HER2- breast CA with OncoType RS <25?

Knowing the differential effect seen with menopausal status in RxPONDER, would you avoid chemotherapy or still offer chemotherapy, given that only 15.9% of premenopausal patients in the endocrine therapy arm were given OFS?

Answer from: Medical Oncologist at Community Practice

Most certainly. The difference between chemotherapy effect in postmenopausal vs. premenopausal women with ER+ breast cancer is not primarily due to a difference in disease biology. It is due to the endocrine effect of chemotherapy in premenopausal women and the lack of that effect in postmenopausal ...

Comments

Medical Oncologist at Genesee Cancer and Blood Disease
What is recommended? Which types of N1 disease?

Medical Oncologist at NYU Langone Medical Center
Agree with @Suleiman A. Massarweh; if she gets che...

Please select the option that best describes you:

Will you use ovarian function suppression in lieu of chemotherapy in premenopausal patients with pN1 ER+ HER2- breast CA with OncoType RS <25?

Related Questions